Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Application of the fluorescent probe 1-anilinonaphthalene-8-sulfonate to the measurement of the nonspecific binding of drugs to human liver microsomes.

McLure JA, Birkett DJ, Elliot DJ, Williams JA, Rowland A, Miners JO.

Drug Metab Dispos. 2011 Sep;39(9):1711-7. doi: 10.1124/dmd.111.039354. Epub 2011 May 24.

PMID:
21610127
2.

In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.

Applegate TL, Birkett DJ, Mcintyre GJ, Jaramillo AB, Symonds G, Murray JM.

Retrovirology. 2010 Oct 9;7:83. doi: 10.1186/1742-4690-7-83.

3.

Interfering ribonucleic acids that suppress expression of multiple unrelated genes.

Passioura T, Gozar MM, Goodchild A, King A, Arndt GM, Poidinger M, Birkett DJ, Rivory LP.

BMC Biotechnol. 2009 Jun 16;9:57. doi: 10.1186/1472-6750-9-57.

4.

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO.

Br J Clin Pharmacol. 2007 Oct;64(4):450-7. Epub 2007 May 22.

5.

The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity.

Rivory L, Tucker C, King A, Lai A, Goodchild A, Witherington C, Gozar MM, Birkett DJ.

Oligonucleotides. 2006 Winter;16(4):297-312.

PMID:
17155906
6.

Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology.

Day RO, Birkett DJ, Miners J, Shenfield GM, Henry DA, Seale JP.

Med J Aust. 2005 Apr 4;182(7):322-3.

PMID:
15804221
7.

Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity.

Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, Miners JO.

Biochemistry. 2004 Jun 22;43(24):7834-42.

PMID:
15196026
8.

Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9.

Boye SL, Kerdpin O, Elliot DJ, Miners JO, Kelly L, McKinnon RA, Bhasker CR, Yoovathaworn K, Birkett DJ.

Xenobiotica. 2004 Jan;34(1):49-60.

PMID:
14742136
9.

Polymorphic hydroxylation of perhexiline in vitro.

Sørensen LB, Sørensen RN, Miners JO, Somogyi AA, Grgurinovich N, Birkett DJ.

Br J Clin Pharmacol. 2003 Jun;55(6):635-8.

10.

Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.

McManus P, Birkett DJ, Dudley J, Stevens A.

Pharmacoepidemiol Drug Saf. 2001 Jun-Jul;10(4):295-300.

PMID:
11760489
11.

A cost-effectiveness approach to drug subsidy and pricing in Australia.

Birkett DJ, Mitchell AS, McManus P.

Health Aff (Millwood). 2001 May-Jun;20(3):104-14.

PMID:
11585158
12.

Changes to the Pharmaceutical Benefits Advisory Committee.

Henry DA, Birkett DJ.

Med J Aust. 2001 Mar 5;174(5):209-10. No abstract available.

PMID:
11280687
13.

The xenobiotic inhibitor profile of cytochrome P4502C8.

Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO.

Br J Clin Pharmacol. 2000 Dec;50(6):573-80.

14.

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.

Miners JO, Coulter S, Birkett DJ, Goldstein JA.

Pharmacogenetics. 2000 Apr;10(3):267-70. No abstract available.

PMID:
10803683
15.

Nonspecific binding of drugs to human liver microsomes.

McLure JA, Miners JO, Birkett DJ.

Br J Clin Pharmacol. 2000 May;49(5):453-61.

16.

Recent changes in the profile of prescription NSAID use in Australia.

McManus P, Henry DA, Birkett DJ.

Med J Aust. 2000 Feb 21;172(4):188. No abstract available.

PMID:
10772594
17.

Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia.

McManus P, Marley J, Birkett DJ, Lindner J.

Br J Clin Pharmacol. 1998 Oct;46(4):409-11.

18.

Prescription use by patients with concession cards.

McManus P, Birkett DJ, Mant A.

Med J Aust. 1998 Sep 7;169(5):285-6. No abstract available.

PMID:
9762074
19.

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Miners JO, Birkett DJ.

Br J Clin Pharmacol. 1998 Jun;45(6):525-38. Review.

20.
21.

Localisation of aryl sulfotransferase expression in human tissues using hybridisation histochemistry and immunohistochemistry.

Windmill KF, Christiansen A, Teusner JT, Bhasker CR, Birkett DJ, Zhu X, McManus ME.

Chem Biol Interact. 1998 Feb 20;109(1-3):341-6. Review.

PMID:
9566757
22.
23.

Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.

Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S.

Br J Clin Pharmacol. 1997 Mar;43(3):245-52.

24.

1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.

Birkett DJ, Miners JO, Valente L, Lillywhite KJ, Day RO.

Br J Clin Pharmacol. 1997 Feb;43(2):197-200.

25.

Allelic and functional variability of cytochrome P4502C9.

Bhasker CR, Miners JO, Coulter S, Birkett DJ.

Pharmacogenetics. 1997 Feb;7(1):51-8.

PMID:
9110362
26.

Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo.

Tassaneeyakul W, Birkett DJ, Pass MC, Miners JO.

Br J Clin Pharmacol. 1996 Dec;42(6):774-8.

27.

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA.

Pharmacogenetics. 1996 Aug;6(4):341-9.

PMID:
8873220
28.
29.

Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.

Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ.

Biochem Pharmacol. 1996 Apr 26;51(8):1003-8.

PMID:
8866821
30.

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.

Graham S, Day RO, Wong H, McLachlan AJ, Bergendal L, Miners JO, Birkett DJ.

Br J Clin Pharmacol. 1996 Apr;41(4):299-304.

31.

The use of caffeine as a metabolic probe for human drug metabolizing enzymes.

Miners JO, Birkett DJ.

Gen Pharmacol. 1996 Mar;27(2):245-9. Review.

PMID:
8919637
32.

Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9.

Miners JO, Birkett DJ.

Methods Enzymol. 1996;272:139-45. No abstract available.

PMID:
8791771
33.

Assays of omeprazole metabolism as a substrate probe for human CYP isoforms.

Birkett DJ, Andersson T, Miners JO.

Methods Enzymol. 1996;272:132-9. No abstract available.

PMID:
8791770
34.

Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.

Tassaneeyakul W, Birkett DJ, Edwards JW, Veronese ME, Tassaneeyakul W, Tukey RH, Miners JO.

J Pharmacol Exp Ther. 1996 Jan;276(1):101-8.

PMID:
8558417
36.

Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.

Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ.

J Pharmacol Exp Ther. 1995 Mar;272(3):1076-81.

PMID:
7891318
37.

Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2.

Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Miners JO.

Pharmacogenetics. 1994 Oct;4(5):281-4. No abstract available.

PMID:
7894501
38.

New uses for allopurinol.

Day RO, Birkett DJ, Hicks M, Miners JO, Graham GG, Brooks PM.

Drugs. 1994 Sep;48(3):339-44. Review. No abstract available.

PMID:
7527756
39.

Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

Andersson T, Miners JO, Veronese ME, Birkett DJ.

Br J Clin Pharmacol. 1994 Aug;38(2):131-7.

40.

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

Andersson T, Miners JO, Veronese ME, Birkett DJ.

Br J Clin Pharmacol. 1994 Jun;37(6):597-604.

41.

Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms.

Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, Miners JO.

Biochem Pharmacol. 1994 May 18;47(10):1767-76.

PMID:
8204093
42.

In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME.

Br J Clin Pharmacol. 1994 May;37(5):413-20.

43.

Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques.

Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO.

Biochem Pharmacol. 1993 Dec 3;46(11):1975-81.

PMID:
8267647
44.

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ.

Br J Clin Pharmacol. 1993 Dec;36(6):521-30.

45.

Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database.

Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D.

Aust J Public Health. 1993 Dec;17(4):345-9.

PMID:
7911332
46.

High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism.

Andersson T, Lagerstrøm PO, Miners JO, Veronese ME, Weidolf L, Birkett DJ.

J Chromatogr. 1993 Sep 22;619(2):291-7.

PMID:
8263101
47.
48.

Development of an Australian drug utilisation database: a report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.

Edmonds DJ, Dumbrell DM, Primrose JG, McManus P, Birkett DJ, Demirian V.

Pharmacoeconomics. 1993 Jun;3(6):427-32. No abstract available.

PMID:
10184168
49.

Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects.

Veronese ME, Miners JO, Rees DL, Birkett DJ.

Pharmacogenetics. 1993 Apr;3(2):86-93.

PMID:
8518838
50.

Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.

Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO.

J Pharmacol Exp Ther. 1993 Apr;265(1):401-7.

PMID:
8474022

Supplemental Content

Loading ...
Support Center